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Summary: A further 3 digoxin radioimmunoassay (RIA) kits have been evaluated for performance and cross-reaction
with digitoxin, spironolactone, canrenone and furosemide (Lasix-Hoechst). Effects of serum protein concentrations
have also been tested. The kits tested were from the following manufacturers:
A) Diagnostic Products Corporation Digoxin RIA Kit.
B) Byk-Mallinckrodt SPAC Digoxin Kit.
C) Boehringer-Mannheim Digoxin RIA Kit.
All kits used a 125I-labelled tracer. Kit A used a conventional liquid phase system using double-antibody separation
for bound and free drug, Kits B and C used a solid-phase antibody coated tube method.
All kits showed a lower cross-reaction to digitoxin than quoted by the manufacturer.
Cross-reaction to spironolactone (Aldactone — Boehringer-Mannheim) was less than 1.50 nmol/I at a serum concentra-
tion of 125 mg/1 Aldactone in all 3 kits. The cross-reaction to canrenone was somewhat higher, 5.2 nmol/1 "digoxin"
being measured in one kit at a serum canrenone concentration of 125 mg/1. There was no cross-reaction with furo-
semide in any kit, even at ä serum concentration of 5 g/1.
The coated-tube assays were affected by serum albumin and globulin concentration changes, one kit showing a
difference of over 50% binding in the range 1—20% albumin. The double-antibody kit did not show dependence on
the concentration of these proteins.
All kits measured digoxin with good reproducibility in the range 0.40—10.0 nmol/1.
/
Eine kritische Überprüfung von weiteren drei Digoxin-Radioimmunoassay-Kits
mit besonderer Rücksicht auf kreuzreagierende Substanzen
Zusammenfassung: Weitere 3 Digoxin Radioimmunoassay (RIA) Kits wurden auf ihre Zuverlässigkeit und ihre Kreuz-
reaktivität mit Digitoxin, Spironolacton, Canrenon und Furosemid getestet. Ebenso wurden die Effekte von Serum-
proteinen evaluiert.
Folgende Kits wurden getestet:
A) Diagnostic Products Corporation Digoxin RIA Kit
B) Byk-Mällirickrodt SPAC Digoxin Kit
C) Boehringer-Mannheim Digoxin RIA Kit.
Alle Kits enthielten einen 12SI-Träcer.
Kit A benutzt eine konventionelle Doppelantikörpermethode, während Kit B und Kit C Antikörper-beschichtete
Röhrchen verwenden. Alle 3 Kits zeigten eine geringere Kreuzreaktivität mit Digitoxin als vom Hersteller angegeben
wurde.
Die Kreuzreaktivität des Spironolactons (Aldactone - Boehringer-Mannheim) war in allen 3 Kits niedrig
(< l »50 nmol/l „Digoxin" bei einer Aldactoiiekonzentration im Serum von 125 mg/1). Dagegen war die Kreuzreaktivi-
tät mit Cänrenon höher (bis 5,2 nmol/1 ,jDigoxin" bei einer Canrenonkonzentration im Serum von 125 mg/1).
Furosemid (Lasix-Hoechst) zeigte keine Kreuzreaktion bei einer Konzentration von 5 g/l.
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Die Coated-Tube Kits zeigten eine erhebliche St rung bei einer nderung der Konzentrationen von Serumalbumin
und |3- und γ-Globulinen. Der maximale Unterschied in der Bindung war > 50% in einem Kit. Der Doppelantik r-
per-Kit zeigte keine solche Abh ngigkeit.
Alle Kits zeigten eine gute Reproduzierbarkeit im Me bereich 0,40-10,0 nmol/1.
Introduction
Following a recent publication (1) in which 6 digoxin
kits were evaluated, one kit (Boehringer-Mannheim) has
been retested with a different antibody, and a further 2
new kits have been included in this follow-up study.
Cross-reaction studies have been made with the most
commonly occurring substances and metabolites that
might be expected to interfere in the assay of serum
digoxin. These were: spironolactone, canrenone, furo-
semide, digitoxin, serum albumin, |8- and γ-globulins.
These substances were tested in concentrations below,
within and above the normal/therapeutic range. As a
measure of the cross-reactivity, the "digoxin'Mevel
was recorded at each concentration of the test-sub-
stance; this is a much better way of expressing the
cross-reaction than the often used and somewhat
misleading concept of displacement at 50% binding.
Tab. 1. Characteristics of the 3 kits.
Pack size
(no. of tests)
Radioactivity
KBq
Range of
standard curve
nmol/1
No. of
standards
How packed
Control serum
included
Amount of
standard/
control sera
DPC-kit
100/500
223/1115
0-10.24
6
lyophilised
human serum
no
2.0 ml zero
standard
1.0 ml others
SPAC-kit
50/100
74/148
0-6.40
6
liquid in
human serum
yes
1.5 ml standard
1.0ml control
serum
B-M-kit
60-88
223
0-6.40
5
lyophilised
human serum
yes
0.5 ml stand-
ard and
control serum
Materials and Methods
The three kits tested were from the following manufacturers:
A) Diagnostic Products Corporation Digoxin Kit
(Biosigma GmbH, D-8000 M nchen 21)
B) Byk-Mallinckrodt SPAC Digoxin Kit
(Byk-Mallinckrodt GmbH, D-6057 Dietzenbach)
C) Boehringer-Mannheim Digoxin Kit
(Boehringer-Mannheim GmbH, D-8132 Tutzing).
In all kits the antigen was labelled with 125I.
The Diagnostic Products Corporation (DPC) kit used a con-
ventional double antibody separation, whereas the Byk-Mallinck-
rodt (SPAC) and Boehringer-Mannheim (B-M) kits both
employed antibody-coated tubes.
Tables 1 and 2 show the composition of the kits and the incuba-
tion schemes.
Digoxin, digitoxin, spironolactone and canrenone were from
Boehringer-Mannheim, D-6800 Mannheim.
Human serum albumin was bought from Sigma GmbH, D-8012
Neubiberg, and human β- and γ-globulins from Miles GmbH,
D-6000 Frankfurt a. M.
Digoxin-free plasma for all studies was obtained from outdated
blood-bank plasma.
All test substances, except the serum proteins, were made up
in digoxin-free plasma.
Furosemide (Lasix-Hoechst, D-6000 Frankfurt a. M.) was used
from the commercially available solution for intravenous
application (10g/l).
Ringer solution (Fresenius) was made up according to DAB 7
and contained 147 mmol/1 Na*, 4.0 mmol/1 K*, 2.25 mmol/1
Ca2+, and 155 mmol/1 CP.
Tab. 2. Incubation and counting schemes.
Serum μΐ
Buffer + tracer μΐ
1st antibody μΐ
2nd antibody μΐ
Incubation
Separation of
bound and
free antigen
Counting
Bq/tube -
zero standard
(new kit)
Counting time* s
Timefor50-tube
assay min
DPC
50
100
100
100
15 min, 37 °C
+ 5 min, room
temperature
2000 μΐ
60 g/l poly-
ethylene
gjycol
10 min 2000 £
aspirate super-
natant
tube*
precipitate
350
30
75
SPAC*
100
1000
φ
φ
60 min, 37 °C
or 180 min,
room
temperature
aspirate tube
contents
tube
200
60
125/265
B-M*
100
500
Φ
Φ ·
60 min,
room
tempera-
ture
aspirate
tube
contents
tube
300
30
100
* coated tube φ not needed . .
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Results
Assay characteristics
Table 3 shows the binding characteristics and the
sensitivity expressed both as the point on the standard
curve lying 3 standard deviations (s. d.) from the zero
standard (see fig. 1 — lower limit of detection), and
as the 50% intercept. The DPC kit showed the best
reproducibility and binding characteristics in the region
of interest, i. e. at both ends of the therapeutic range.
The inter- and intra-assay coefficients of variation (CV)
are shown in table 4. Again, the DPC kit gave the best
results.
156 625 25.0
Glycoside [nmol/l]
100.0
Fig. 1. Standard curve for digoxin ( ) and digitoxin ( )
using the SPAC digoxin kit. The curve was constructed
using a spline approximation and the lower detection
limits. The 50% intercept values are: digoxin 2.21 mmol/1;
digitoxin 14.4 nmol/l. The vertical bars on the standard
curves show the +1 to -1 s.d. range of the binding of the
standards. The horizontal bar shows the lower limit of
detection.
Cross-reactivity studies
Table 5 shows the reaction of the kits with digoxin and
digitoxin in glycoside-free plasma. Table 6 shows the
cross-reaction of spironolactone and canrenone in the
kits. The cross-reaction is measured as "digoxin"
measured at each point tested. This is the better way
of showing the interference of spironolactone and
canrenone, which can be present in serum at concentra-
tions in excess of 1000 times those of digoxin, and
where a percent cross-reactivity can appear deceptively
low.
The cross-reaction of digitoxin was lowest in the DPC
kit and highest in the SPAC kit. The latter kit can be
used to measure digitoxin in serum (see below). All kits
measured digoxin within acceptable ranges when the
kit standard curve was used as reference, although in the
early SPAC kits, there was a considerable negative bias
before the kit standards were changed for standards
containing correct digoxin concentrations.
The cross-reactivity of spironolactone and canrenone
were lowest in the B-M kit. In all kits, however, can-
renone reacted with the antibody more than spironolac-
tone. *
The cross-reaction with furosemide was not detected
in any of the 3 kits tested, even at a concentrations of
Sg/l-
Tab. 3. Standard curve reproducibility and sensitivity - mean and standard deviation.
Sensitivity1· nmol/l
50% intercept
% binding of zero standard
0.51 nmol/l standard
0.64
0.99vm
.-f <
1.28
2.24
2.56
3.80
5.12
6.40
10.24
No, of assays used for
calculation of mean and S. D.
DPC,
Room temperature
0.19 ± 0.07
2.05 ± 0.17
-^
77.9 ± 2.05
62.5 ± 2.30
44^2 ± 2.05
—27.9 ± 1.46
—16.6 ± 1.23
30
SPAC,
37 °C
0.21 ± 0.06
2.33 ± 0.37
83.0 ± 3.08
—
~
65.2 ± 4.76
-^
47.0 ± 4.27
34.2 ± 4.21
—24.0 ± 4.39
—
10
B-M,
Room
0.34
3.57
-
—
81.9 ±
—
60.9 ±
—
46.9 ±
—
33.8 ±
—
10
temperature
±0.04
± 0.56
2.73
1.43
4.76
5.27
* Sensitivity = Value on standard curve X 3 S. P. from zero.
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Tab. 4. Inter- and intra-assay precision with different control sera.
Intra-assay precision Intra-assay precision
nmol/1
CV% N
Inter-assay precision
nmol/1
CV% N
l.DPC
2. SPAC
3. B-M
Quality control serum
RIACON 1
RIACON 2
Laboratory Pool D 1
Laboratory Pool D 2
RIACON 1
RIACON 2
NMSI
NMSI
NMS Ha
1.63
4.07
1.15
2.88
1.06
2.95
1.07
0.91
2.89
0.10
0.22
0.07
0.15
0.11
0.18
0.08
0.05
0.23
6.7
5.3
6.2
5.2
12.2
6.1
7.5
5.6
8.0
24
24
20
20
20
20
20
19
19
L45
4.00
1.20
3.00
1.00
2.88
—
0,89
2.63
0.16
0.37
0.11
0.22
0.15
0.23
—
0.15
0.32
11.0
9.2
9.0
7.4
15.0
8.1
—
14.8
12.2
53
53
24
24
20
20
—
10
10
Tab. 5. Cross-reactivity of Digitoxin and Digoxin - read from kit standard curve.
Measured "Digoxin"
(a) nmol/1 (b) expressed as % digitoxin/digoxin in the test sera
Digitoxin
nmol/1
0
1.56
3.12
6.25
12.5
25.0
50.0
100
Digoxin
nmol/1
0
0.31
0.62
1.25
2.5
5.0
10.0
DPC
a
<0.1
< 0.1
< 0.1
0.12
0.16
0.17
0.47
0.73
<0.1
0.24
0.56
0.96
2.45
4.48
8.85
b
_
-
-
1.92
1.28
0.68
0.44
0.73
_
77.5
90.3
76.8
98.0
89.6
88.5
SPAC
a
<0.1
0.36
0.53
1.38
2.00
2.81
4.05
5.88
<0.1
0.33
0.61
1.44
2.26
4.19
8.90
b
23.0
17.0
22.1
16.0
11.2
8.1
5.88
106
98.4
115
90.4
83.8
89.0
B-M
a
<0.1
0.19
0.34
0.52
0.73
0.96
1.61
3.49
<0.1
0.44
0.89
1.41
2.41
5.92
12.11
b
__
12.2
10.9
8.32
5.84
3.84
3.22
3.49
_.
141
142
113
96
118
121
Effects of different serum-proteins
on the maximum binding
Table 7 shows the effects of albumin (1-20%) and
|3- and -globulins (1-5%) on the maximum binding.
The proteins were dissolved in Ringer solution, so that
only the protein under test was present in the tube. The
100% binding is the binding given by the zero standard
in each kit. Both coated tube kits showed large differ-
ences in binding at different albumin concentrations;
with the globulins, and with low concentrations of
albumin, binding was well above 100%. The DPC kit,
using conventional double antibody separation was
affected little or not at all by the serum protein con-
centration.
Effects ofaldactone therapy
on measured digoxin concentrations
Table 8 shows .the measured digoxin concentration in
12 patients on spironolactone therapy. The glycoside
and spironolactone dosages are shown, as well as serum
creatinine as the index of renal function. Large discrep-
ancies are to be seen in the recorded digoxin levels in
2 patients (Nos. 130 and 139). In the other 10 patients
no trend is observable between results from the different
kits.
Standards measured in all kits
Table 9 shows the standards in the 3 kits as measured
in the other 2 kits. For the SPAC kit the results in
brackets were those from the earlier kits with the wrong
concentrations above 1.28 nmol/1. the DPC kit measures
the expected digoxin values in all kits. The coated tube
kits showed some discrepancies. All standards showed
a normal electrophöresis pattern \Vith a total serum
protein of between 52 and 63 g/L.
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Tab. 6. Cross-reactivity of Spironolactone and Canrenone -
read off against kit standard curve.
Spironolactone
mg/1
0
0.975
1.95
3.90
7.80
15.6
31.2
62.5
125
Canrenone
mg/1
0
0.125
0.250
0.500
0.975
1.95
3.90
7.80
15.6
31.2
62.5
125
Measured
nmol/1
DPC
<0.1
<<u
< o!i
0.14
0.19
0.35
0.69
0.94
<0.1
θ'.13
0.18
0.20
0.37
0.42
0.43
0.98
1.67
2.89
3.57
"Digoxin"
SPAC
<0.1
< 0.1
0.17
0.33
0.43
0.50
0.59
0.87
<0.1
<αί
< 0.1
0.35
0.41
0.58
0.78
1.23
2.17
3.81
5.61
B-M
<0.1
< 0.1
0.15
0.10
0.22
0.36
0.56
0.84
<0.1
<αί
< 0.1
< 0.1
ΟΪ28
0.28
0.41
0.57
0.94
1.76
2.54
The measurement ofdigitoxin in serum
with the SPAC kit
Figure 1 shows the standard curves for digoxin and
digitoxin in the SPAC digoxin kit. Both curves were
set up using pure digoxin or digitoxin added to digitalis-
free serum. The lowest detectable limit for digitoxin is
around 1 nmol/1 with a 50% intercept of 14.4 nmol/1.
The kit allows measurement ofdigitoxin up to 50 nmol/1
which covers both therapeutic and toxic levels.
Correlation of results
Table 10 shows the correlation of results in 67 patients
undergoing digoxin therapy. The sera were measured in
all kits in a single assay, the assays being carried out on
the same day. All correlation coefficients are, as to be
expected, highly significant but do not approach the
ideal regression equation with a = 0 and b = .1 .
Discussion
The cross-reaction of digoxin antisera with digitoxin
can be used to advantage when it is large enough to
allow a digitoxin standard curve to be plotted which
covers the range of digitoxin found in patients under-
Tab. 7. Effect of albumin and globulin concentration on the
maximum binding.
Albumin (g/1) in
Ringer solution
10
20
40
60
80
120
160
200
^Globulin (g/1) in
Ringer solution
10
20
30
40
50
rGlpbulin (g/1) in
Ringer solution
10
20
30
40
50
% binding -
DPC
100
102
100
101
101
97
98
98
102
104
104
104
1Q4
103
104
106
106
106
100% = kit zero standard
SPAC B,M
130
127
108
102
100
92
88
79
142
140
139
135
133
145
144
142
138
139
133
139
124
129
128
113
108
105
134
130
126
118
114
136
133
134
132
128
levels of digitoxin in serum as found by Smith (2) were
22 ± 10 nmol/1 for non-toxic cases, and 44 ± 8 nmol/1
for toxic cases.
The cross-reaction of digoxin antisera with digitoxin
is not linear throughout the concentration range as
seen in table 5, and it is often confusing to read in kit
instructions that for example, the cross-reaction of
the kit antisera to digitoxin is 10%.
The SPAC-kit allows measurement of digitoxin in
serum as seen in figure 1. As a practical example, a
patient was admitted to the emergency ward, un-
conscious and suspected of having digitalis overdose.
The preparation was unknown. With the SPAC-kit the
patient serum gave a "digoxin" level of 3.42 nmol/1
and a "digitoxin" level of 38 nmol/1. The DPC-kit gave
a "digoxin" level of 0.28 nmol/1. Both SPAC values
were in the toxic range whereas that from the DPC-kit
was under the therapeutic range. The digitalis prepara-
tion was later confirmed to be Digimerck, a digitoxin
preparation. The SPAC-kit gave useful information in
this case arid the DPC-kit would have registered no
case of intoxication due to its low cross-reactivity to
digitoxin!
The coated tube kits gave problems with abnormally
serum protein concentrations which could be a
hindrance in the case of serum from dialysis patients
and others with dysproteinaemia. Effects of serum
proteins and renal insufficiency have been described
in part for both 12SI- and 3H-methods (3-7). It has
been known for some time that simultaneous Spirono-
lactone (Aldactone) treatment and digoxin therapy
J. Clin. Chem. Clin. Biochem. / Vol. 17,. 1979 / No. 2
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Tab. 8. Measured Digoxin concentrations in 12 patients on Spironolactonc therapy*
Patien t N o. Digox in d ose
19
21
24
43
53
90
106
107
124
130
139
175
mg/d
0.375 L*
0.125 L
0.250 L
0.062 L
0.250 L
0.400 N**
0.250 L
0.250 L
0.375 L
0.125 L
0.500 L
0.300 N
Application Spironolactone Creatinine
oral
oral
oral
i. v.
L v.
oral
oral
oral
oral
i.v.
oral
oral
mg/d
100
200
200
200
400
200
200
200
200
200
800
100
mg/1
9
17
—
22
-
10
10
14
9
11
28
5
Measured Digoxin levels nmol/1
DPC
LO
2.6
2.8
2.4
1.1
2.4
2.2
0.75
3.9
10.0
7.5
1.0
SPAC
0.66
2.1
1.7
3.0
1.4
3.2
1.8
1.1
5.6
8.6
4.6
0.74
B-M
1.2
2.4
2.3
2.9
1.7
2.8
2.5
1.1
4.2
6.2
4.9
1.2
* L = Lanicor (Digoxin, Boehringer-Männheim)
** N = Novodigal (0-Acetyl-Digöxin, Merck)
Tab. 9. Measured Digoxin concentration of standards in other
kits.
Tab. 10. Correlation between the 3 kits, using sera from patients
undergoing Digoxin therapy.
DPC standards
nmol/1
0
0.64
1.28
2.56
5.12
10.24
*SPAC
standards
nmol/1
0
0.51
1.28
2.56
3.84
6.40
Boehringer-
Mannheim
standards
nmol/1
0
0.99
2.24
3.82
6.40
DPC kit
—
-
-
-
-
—
(< 0.1) < 0.1
(0.57) 0.50
(1.20) L27
(2.52) 2.55
(4.53) 3.78
(8.35) 6.30
<0.1
1.05
2.21
3.58
6.66
SPAC kit
« 0.1) < 0.1
« 0.1) 0.25
(0.43) 0.78
(1.06) 1.43
(2.51) 2.90
(5.39) 7.55
—
-
-
-
—
—
(< 0.1) < 0.1
(0.31) 0.50
(1.04) 1.45
(1.74) 2.35
(3.11) 5.00
B-M kit
0.23
0.87
1.30
2.16
5.75
11.84
« 0.1) < 0.1
(0.33) 0.29
(0.83) 0.86
(1.88) 2.00
(3.34) 3.49
(5.11) 4.55
_
_
—
—
—
During this test the standards were changed. The values of
the old standards as measured are shown in parentheses.
Values are the means from at least 3 assays in which each
standard was run in duplicate.
often give rise to toxic serum digoxin levels, even though
no symptoms of an overdose are evident. Spironolactone
has a similar structure to digoxin and has a digoxin
antagonist effect (8). It also cross-reacts with some
digoxin antisera which can cause havoc, since Spirono-
lactone may be present in serum at concentrations
DPC v SPAC
DPC v B-M
SPAC v ß-M
a
-0.01
0.36
0.26
b
0.87
0.86
0.94
r
0.928
0.896
0.911
67
67
67
Linear regression equation y = a + bx
The first kit is on the x-axis
In all cases < 0.001.
Digoxin levels measured in the three kits in these 67 patients
were (mean and range)
DPC Kit 1.82 nmol/1 (0.30-10.0 nmol/1)
SPAC Kit 1.64 nmol/1 (0.37-8.60 nmol/1)
B-M Kit 1.60 nmol/1 (0.41-6.20 nmol/1)
above 1000 times that of digoxin. Spironolactone is
rapidly metabolised in the body to several metabolites
with differing biological and immunological properties
(9). At least 9 metabolites have been classified (9) of
which canrenone and canrenoic acid are the main ones
(9-10).
The affinity of canrenone for the digoxin antisera was
higher than that shown by Spironolactone for the anti-
•sera tested here, although the concentrations of
canrenone in serum are usually much lower than those
for Spironolactone. Assuming a complete distribution in
the blood, the maximum Spironolactone levels after a
200 mg i/v dose with a blood volume of 5 liters would
be 40 mg/1. The maximum canrenone levels in serum
are obtained about 2 h after administration of Spirono-
lactone. After a single dose of 200 mg Spironolactone,
the maximal canrenone concentration observed by
Karim and co-workers was 0.40 mg/1 (9). Over longer
periods of Spironolactone therapy, canrenone accumu-
lates in the serum, its half-life being. 18-22 h. A steady-
state is reached after 7—10 days of spiroriolactone
J. Clin. Chem. Clin. Biochem. / Vol. 17, 1979 /No. 2
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therapy, when the minimum canrenone levels measured
(24 h after the last spironolactone dose) were: up to
0.9 mg/1 for 200 mg, up to 1.7 mg/1 for 300 mg and up
to 2.6 mg/1 for 400 mg spironolactone per day (9). In
one case of congestive heart failure, serum canrenone
levels of 4.3 mg/1 were measured in a patient taking
Soldactone (potassium canrenoate). Other metabolites
of spironolactone and canrenoic acid are known to
have halflives of longer than 50 days (9), and are there-
fore likely to accumulate in the body during therapy.
These metabolites have neither been characterised nor
tested for reaction with digoxin antisera. Although
only minimally elevated digoxin levels may be expected
in serum of patients on spironolactone therapy, un-
expectedly high levels are occasionally seen in some
kits, as seen in patients 130 and 139 in Table 8 with
the DPC-kit. Neither of these patients had ECG patterns
which would indicate digitalis poisoning. In rats under-
going digoxin therapy with and without spjronolactone
(8), it was found that spironolactone increased the
excretion of digoxin metabolites from 72 to 98% of
the given digoxin dose; this may indicate, that under
Aldactone therapy, there is an increased metabolism
of digoxin to less biologically active metabolites which
may still show immunoreactivity with certain antisera
to digoxin. This, together with the antagonist action of
spironolactone (8), may explain why some patients
exhibit high immunoreactive digoxin levels without the .
accompanying ECG changes and without complaining
of "yeUow-vision" often seen in digitalis intoxication
patients.
Bearing these facts in mind, care must be used when
interpreting results from patients on either spirono-
lactone or canrenoate therapy.
There was no cross-reaction of the three antibodies
to furosemide, which is probably to be expected as
this molecule shows no spatial similarities to digoxin.
The coefficients of variation, both intra- and inter-
assay, were greater in the coated tube kits, as already
shown previously (1). The stability of the standard
curves in serial assays is good, but not good enough
for a short-cut suggested by Boehringer-Mannheim in
their kit instructions. Here, it is stated that the standard
curve tubes used in one assay can be stored and used
in subsequent assays over the next 14 days, provided
that the quality-control serum, supplied in the kit, and
run with each assay, gives results from this standard
curve which lie within the prescribed limits. This is a
false economy step which contravenes all accepted
quality-control concepts.
The instructions contained in each kit gave detailed
information on carrying out the test, and in the case
of the DPC and SPAC kits, also the clinical relevance
of the test. The DPC-kit in its original form had more
useful data on recovery experiments and inter- and
intra-assay variation.
The SPAC-kit contained one mistake in the French
and English versions, that of the cross-reaction of the
antibody with j8-acetyl digoxin at 40%, whereas
in the German edition it is given, correctly, at 90%.
To conclude, this study has shown that of the 3 kits
tested none is ideal for all situations, a finding which
repeats those of an earlier investigation (1).
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